Synthesis, in vitro evaluation and molecular docking studies of novel naphthoisoxazolequinone carboxamide hybrids as potential antitumor agents

References

• World Health Organization, “Cancer,” last modified September 21, 2021, http://www.who.int/news-room/fact-sheets/detail/cancer (accessed November 06, 2021).
   Google Scholar
• J. Schüz, C. Espina, and C. P. Wild, “Primary Prevention: A Need for Concerted Action,” Molecular Oncology 13, no. 3 (2019): 567–78. doi:10.1002/1878-0261.12432.
   PubMed Web of Science ®Google Scholar
• World Health Organization, “Global Cancer Observatory: Cancer Today, Lyon: International Agency for Research on Cancer”, https://gco.iarc.fr/today (accessed March 26, 2021).
   Google Scholar
• World Health Organization, “Cancer Tomorrow, Lyon: International Agency for Research on Cancer”, https://gco.iarc.fr/tomorrow/home (accessed July 24, 2021).
   Google Scholar
• M. Manickam, P. R. Boggu, J. Cho, Y. J. Nam, S. J. Lee, and S. H. Jung, “Investigation of Chemical Reactivity of 2-Alkoxy-1,4-Naphthoquinones and Their Anticancer Activity,” Bioorganic & Medicinal Chemistry Letters 28, no. 11 (2018): 2023–8. doi:10.1016/j.bmcl.2018.04.060.
   PubMed Web of Science ®Google Scholar
• A. Ghods, J. Gilbert, J. R. Baker, C. C. Russell, J. A. Sakoff, and A. McCluskey, “A Focused Library Synthesis and Cytotoxicity of Quinones Derived from the Natural Product Bolinaquinone,” Royal Society Open Science 5, no. 4 (2018): 171189. doi:10.1098/rsos.171189.
   PubMed Web of Science ®Google Scholar
• F. Wang, X. Yao, Y. Zhang, and J. Tang, " “Synthesis, Biological Function and Evaluation of Shikonin in Cancer Therapy,” Fitoterapia 134 (2019): 329–39. doi:10.1016/j.fitote.2019.03.005.
   PubMed Web of Science ®Google Scholar
• B. Pang, J. De Jong, X. Qiao, L. F. A. Wessels, and J. Neefjes, " “Chemical Profiling of the Genome with anti-Cancer Drugs Defines Target Specificities,” Nature Chemical Biology 11, no. 7 (2015): 472–80. doi:10.1038/nchembio.1811.
   PubMed Web of Science ®Google Scholar
• X. Liang, Q. Wu, S. Luan, Z. Yin, C. He, L. Yin, Y. Zou, Z. Yuan, L. Li, X. Song, et al, “A Comprehensive Review of Topoisomerase Inhibitors as Anticancer Agents in the past Decade,” European Journal of Medicinal Chemistry 171 (2019): 129–68. doi:10.1016/j.ejmech.2019.03.034.
   PubMed Web of Science ®Google Scholar
• I. Hueso-Falcón, Á. Amesty, L. Anaissi-Afonso, I. Lorenzo-Castrillejo, F. Machín, and A. Estévez-Braun, “Synthesis and Biological Evaluation of Naphthoquinone-Coumarin Conjugates as Topoisomerase II Inhibitors,” Bioorganic & Medicinal Chemistry Letters 27, no. 3 (2017): 484–9. doi:10.1016/j.bmcl.2016.12.040.
   PubMed Web of Science ®Google Scholar
• V. Marković, A. Janićijević, T. Stanojković, B. Kolundžija, D. Sladić, M. Vujčić, B. Janović, L. Joksović, P. T. Djurdjević, N. Todorović, et al, “Synthesis, Cytotoxic Activity and DNA-Interaction Studies of Novel Anthraquinone-Thiosemicarbazones with Tautomerizable Methylene Group,” European Journal of Medicinal Chemistry 64 (2013): 228–38. doi:10.1016/j.ejmech.2013.03.071.
   PubMed Web of Science ®Google Scholar
• V. Kuete, A. R. Nanfack Donfack, A. T. Mbaveng, M. Zeino, P. Tane, and T. Efferth, “Cytotoxicity of Anthraquinones from the Roots of Pentas Schimperi towards Multi-Factorial Drug-Resistant Cancer Cells,” Investigational New Drugs 33, no. 4 (2015): 861–9. doi:10.1007/s10637-015-0268-9.
   PubMed Web of Science ®Google Scholar
• T. B. Gontijo, R. P. de Freitas, F. S. Emery, L. F. Pedrosa, J. B. Vieira Neto, B. C. Cavalcanti, C. Pessoa, A. King, F. de Moliner, M. Vendrell, et al, “On the Synthesis of Quinone-Based BODIPY Hybrids: New Insights on Antitumor Activity and Mechanism of Action in Cancer Cells,” Bioorganic & Medicinal Chemistry Letters 27, no. 18 (2017): 4446–56. doi:10.1016/j.bmcl.2017.08.007.
   PubMed Web of Science ®Google Scholar
• H. Z. Zhang, Z. L. Zhao, and C. H. Zhou, " “Recent Advance in Oxazole-Based Medicinal Chemistry,” European Journal of Medicinal Chemistry 144 (2018): 444–92. doi:10.1016/j.ejmech.2017.12.044.
   PubMed Web of Science ®Google Scholar
• N. Agrawal, and P. Mishra, “The Synthetic and Therapeutic Expedition of Isoxazole and Its Analogs,” Medicinal Chemistry Research: An International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents 27, no. 5 (2018): 1309–44. doi:10.1007/s00044-018-2152-6.
   PubMed Web of Science ®Google Scholar
• J. Zhu, J. Mo, H. Zhi Lin, Y. Chen, and H. Peng. Sun, “The Recent Progress of Isoxazole in Medicinal Chemistry,” Bioorganic & Medicinal Chemistry 26, no. 12 (2018): 3065–75. (doi:10.1016/j.bmc.2018.05.013.
   PubMed Web of Science ®Google Scholar
• M. Zia, S. Hameed, I. Ahmad, N. Tabassum, and S. Yousuf, “Regio-Isomeric Isoxazole Sulfonates: Synthesis, Characterization, Electrochemical Studies and DNA Binding Activity,” Journal of Molecular Structure 1220 (2020): 128635. doi:10.1016/j.molstruc.2020.128635.
   Web of Science ®Google Scholar
• S. T. Reddy, J. J. Mendonza, V. K. K. Makani, M. P. Bhadra, and V. M. Uppuluri, " “Synthesis of Some Novel Methyl β-Orsellinate Based 3, 5-Disubstituted Isoxazoles and Their anti-Proliferative Activity: Identification of Potent Leads Active against MCF-7 Breast Cancer Cell,” Bioorganic Chemistry 105 (2020): 104374. doi:10.1016/j.bioorg.2020.104374.
   PubMed Web of Science ®Google Scholar
• T. D. Bhatt, D. G. Gojiya, P. L. Kalavadiya, and H. S. Joshi, “Rapid, Greener and Ultrasound Irradiated One-Pot Synthesis of 4-(Substituted-1H-Pyrazol-4-yl)Methylene)-3-Isopropylisoxazol-5(4H)-Ones and Their In Vitro Anticancer Activity,” ChemistrySelect 4, no. 37 (2019): 11125–9. doi:10.1002/slct.201902164.
   Web of Science ®Google Scholar
• S. Ravula, R. R. Bobbala, and B. Kolli, “Synthesis of Novel Isoxazole Functionalized Pyrazolo[3,4‐b]Pyridine Derivatives; Their Anticancer Activity,” Journal of Heterocyclic Chemistry 57, no. 6 (2020): 2535–8. doi:10.1002/jhet.3968.
   Web of Science ®Google Scholar
• E. T. Warda, I. A. Shehata, M. B. El-Ashmawy, and N. S. El-Gohary, “New Series of Isoxazole Derivatives Targeting EGFR-TK: Synthesis, Molecular Modeling and Antitumor Evaluation,” Bioorganic & Medicinal Chemistry 28, no. 21 (2020): 115674. doi:10.1016/j.bmc.2020.115674.
   PubMed Web of Science ®Google Scholar
• A. Naouri, A. Djemoui, M. R. Ouahrani, M. B. Lahrech, N. Lemouari, D. H. A. Rocha, H. Albuquerque, R. F. Mendes, F. A. Almeida Paz, L. A. Helguero, et al, “Multicomponent and 1,3-Dipolar Cycloaddition Synthesis of Triazole- and Isoxazole-Acridinedione/Xanthenedione Heterocyclic Hybrids: Cytotoxic Effects on Human Cancer Cells,” Journal of Molecular Structure 1217 (2020): 128325. doi:10.1016/j.molstruc.2020.128325.
   Web of Science ®Google Scholar
• R. M. Mohareb, K. M. H. Hilmy, and Y. A. Elshehawy, “Discovery of New Thiophene, Pyrazole, Isoxazole Derivatives as Antitumor, c-Met, Tyrosine Kinase and Pim-1 Kinase Inhibitors,” Bulletin of the Chemical Society of Ethiopia 32, no. 2 (2018): 285–308. doi:10.4314/bcse.v32i2.9.
   Web of Science ®Google Scholar
• R. M. Mohareb, F. M. Manhi, M. A. A. Mahmoud, and A. Abdelwahab, “Uses of Dimedone to Synthesis Pyrazole, Isoxazole and Thiophene Derivatives with Antiproliferative, Tyrosine Kinase and Pim-1 Kinase Inhibitions,” Medicinal Chemistry Research 29, no. 8 (2020): 1536–51. doi:10.1007/s00044-020-02579-4.
   Web of Science ®Google Scholar
• M. A. Barmade, P. R. Murumkar, M. K. Sharma, and M. R. Yadav, “Medicinal Chemistry Perspective of Fused Isoxazole Derivatives,” Current Topics in Medicinal Chemistry 16, no. 26 (2016): 2863–83. doi:10.2174/1568026616666160506145700.
   PubMed Web of Science ®Google Scholar
• Raquib Alam, Divya Wahi, Raja Singh, Devapriya Sinha, Vibha Tandon, and Abhinav Grover, “Design, Synthesis, Cytotoxicity, HuTopoIIα Inhibitory Activity and Molecular Docking Studies of Pyrazole Derivatives as Potential Anticancer Agents,” Bioorganic Chemistry 69 (2016): 77–90. doi:10.1016/j.bioorg.2016.10.001.
   PubMed Web of Science ®Google Scholar
• D. A. Al-Turki, M. A. Al-Omar, L. A. Abou-Zeid, I. A. Shehata, and M. S. Al-Awady, “Design, Synthesis, Molecular Modeling and Biological Evaluation of Novel Diaryl Heterocyclic Analogs as Potential Selective Cyclooxygenase-2 (COX-2) Inhibitors,” Saudi Pharmaceutical Journal : SPJ : The Official Publication of the Saudi Pharmaceutical Society 25, no. 1 (2017): 59–69. doi:10.1016/j.jsps.2015.07.001.
   PubMed Web of Science ®Google Scholar
• A. Kamal, A. B. Shaik, B. B. Rao, I. Khan, G. Bharath Kumar, and N. Jain, “Design and Synthesis of Pyrazole/Isoxazole Linked Arylcinnamides as Tubulin Polymerization Inhibitors and Potential Antiproliferative Agents,” Organic & Biomolecular Chemistry 13, no. 40 (2015): 10162–78. doi:10.1039/c5ob01257k.
   PubMed Web of Science ®Google Scholar
• K. S. Rakesh, S. Jagadish, K. S. Balaji, F. Zameer, T. R. Swaroop, C. D. Mohan, S. Jayarama, and K. S. Rangappa, “3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer,” Inflammation 39, no. 1 (2016): 269–80. doi:10.1007/s10753-015-0247-5.
   PubMed Web of Science ®Google Scholar
• C. Sobolewski, C. Cerella, M. Dicato, L. Ghibelli, and M. Diederich, “The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies,” International Journal of Cell Biology 2010 (2010): 215158. doi:10.1155/2010/215158.
   PubMedGoogle Scholar
• B. Liu, L. Qu, and S. Yan, “Cyclooxygenase-2 Promotes Tumor Growth and Suppresses Tumor Immunity,” Cancer Cell International 15 (2015): 106. doi:10.1186/s12935-015-0260-7.
   PubMed Web of Science ®Google Scholar
• Y. Tsuboi, T. Ichida, S. Sugitani, T. Genda, J. Inayoshi, M. Takamura, Y. Matsuda, M. Nomoto, and Y. Aoyagi, “Overexpression of Extracellular Signal-Regulated Protein Kinase and Its Correlation with Proliferation in Human Hepatocellular Carcinoma,” Liver International : official Journal of the International Association for the Study of the Liver 24, no. 5 (2004): 432–6. doi:10.1111/j.1478-3231.2004.0940.x.
   PubMed Web of Science ®Google Scholar
• B. Liang, S. Wang, X. Zhu, Y. Yu, Z. Cui, and Y. Yu, “Increased Expression of Mitogen-Activated Protein Kinase and Its Upstream Regulating Signal in Human Gastric Cancer,” World Journal of Gastroenterology 11, no. 5 (2005): 623–8. doi:10.3748/wjg.v11.i5.623.
   PubMed Web of Science ®Google Scholar
• M. Gagliardi, M. K. Pitner, J. Park, X. Xie, H. Saso, R. A. Larson, R. M. Sammons, H. Chen, Caimiao Wei, H. Masuda, et al, “Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer,” Scientific Reports 10, no. 1 (2020):s41598-020-65250-3. doi:10.1038/s41598-020-65250-3.
   Google Scholar
• M. Yang, and C. Z. Huang, “Mitogen-Activated Protein Kinase Signaling Pathway and Invasion and Metastasis of Gastric Cancer,” World Journal of Gastroenterology 21, no. 41 (2015): 11673–9. doi:10.3748/wjg.v21.i41.11673.
   PubMed Web of Science ®Google Scholar
• A. K. Pullikuth, and A. D. Catling, “Scaffold Mediated Regulation of MAPK Signaling and Cytoskeletal Dynamics: A Perspective,” Cellular Signalling 19, no. 8 (2007): 1621–32. doi:10.1016/j.cellsig.2007.04.012.
   PubMed Web of Science ®Google Scholar
• R. Kalirajan, A. Pandiselvi, B. Gowramma, and P. Balachandran, “In-Silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer,” Current Drug Research Reviews 11, no. 2 (2019): 118–28. doi:10.2174/2589977511666190912154817.
   PubMedGoogle Scholar
• A. Mangoni, J. Eynde, J. Jampilek, D. Hadjipavlou-Litina, H. Liu, J. Reynisson, M. Sousa, P. Gomes, K. Prokai-Tatrai, T. Tuccinardi, et al, “Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–4,” Molecules 24, no. 13 (2019): 130. doi:10.3390/molecules24010130.
   Web of Science ®Google Scholar
• L. Scotti, F. Mendonça-Junior, and M. Scotti, “Editorial (Thematic Issue: Hybrid Compounds as Multitarget Agents in Medicinal Chemistry - Part II),” Current Topics in Medicinal Chemistry 17, no. 9 (2017): 957–8. doi:10.2174/156802661709170213205211.
   PubMed Web of Science ®Google Scholar
• H. A. Alzahrani, M. M. Alam, A. A. Elhenawy, A. M. Malebari, and S. Nazreen, “Synthesis, Antiproliferative, Docking and DFT Studies of Benzimidazole Derivatives as EGFR Inhibitors,” Journal of Molecular Structure 1253, no. 1253 (2022): 132265. doi:10.1016/j.molstruc.2021.132265.
   Google Scholar
• M. M. Alam, “1,2,3-Triazole Hybrids as Anticancer Agents: A Review,” Archiv Der Pharmazie 355, no. 1 (2022): 2100158. doi:10.1002/ardp.202100158.
   PubMed Web of Science ®Google Scholar
• A. S. A. Almalki, S. Nazreen, A. M. Malebari, N. M. Ali, A. A. Elhenawy, A. A. A. Alghamdi, A. Ahmad, S. Y. M. Alfaifi, M. A. Alsharif, and M. M. Alam, “Synthesis and Biological Evaluation of 1,2,3-Triazole Tethered Thymol-1,3,4-Oxadiazole Derivatives as Anticancer and Antimicrobial Agents,” Pharmaceuticals 14, no. 9 (2021): 866– 18. doi:10.3390/ph14090866.
   Web of Science ®Google Scholar
• M. M. Alam, M. M. A. M. Malebari, N. Syed, T. Neamatallah, A. S. A. Almalki, A. A. Elhenawy, R. J. Obaid, and M. A. Alsharif, “Design, Synthesis and Molecular Docking Studies of Thymol Based 1,2,3-Triazole Hybrids as Thymidylate Synthase Inhibitors and Apoptosis Inducers against Breast Cancer Cells,” Bioorganic & Medicinal Chemistry 38, no. 38 (2021): 116136. doi:10.1016/j.bmc.2021.116136.
   PubMedGoogle Scholar
• A. Borrelli, A. L. Tornesello, M. L. Tornesello, and F. M. Buonaguro, “Cell Penetrating Peptides as Molecular Carriers for anti-Cancer Agents,” Molecules 23, no. 2 (2018): 295. doi:10.3390/molecules23020295.
   PubMed Web of Science ®Google Scholar
• C. F. Albright, N. Graciani, W. Han, E. Yue, R. Stein, Z. Lai, M. Diamond, R. Dowling, L. Grimminger, S.-Y. Zhang, et al, “Matrix Metalloproteinase-Activated Doxorubicin Prodrugs Inhibit HT1080 Xenograft Growth Better than Doxorubicin with Less Toxicity,” Molecular Cancer Therapeutics 4, no. 5 (2005): 751–60. doi:10.1158/1535-7163.MCT-05-0006.
   PubMed Web of Science ®Google Scholar
• N. Dias, J. F. Goossens, B. Baldeyrou, A. Lansiaux, P. Colson, A. Di. Salvo, J. Bernal, A. Turnbull, D. J. Mincher, and C. Bailly, “Oxoazabenzo[de]Anthracenes Conjugated to Amino Acids: synthesis and Evaluation as DNA-Binding Antitumor Agents,” Bioconjugate Chemistry 16, no. 4 (2005): 949–58. doi:10.1021/bc050065x.
   PubMed Web of Science ®Google Scholar
• A. Molinari, A. Oliva, C. Ojeda, J. M. Miguel Del Corral, M. A. Castro, F. Mollinedo, and A. San Feliciano, “Synthesis and Evaluation as Antitumor Agents of 1,4-Naphthohydroquinone Derivatives Conjugated with Amino Acids and Purines,” Archiv Der Pharmazie 346, no. 12 (2013): 882–90. doi:10.1002/ardp.201300137.
   PubMed Web of Science ®Google Scholar
• A. Molinari, A. Oliva, M. Arismendi-Macuer, L. Guzmán, M. Fuentealba, M. Knox, R. Vinet, and A. San Feliciano, “New 1H-Benzo[f]Indazole-4,9-Diones Conjugated with C-Protected Amino Acids and Other Derivatives: Synthesis and In Vitro Antiproliferative Evaluation,” Molecules 20, no. 12 (2015): 21924–38. doi:10.3390/molecules201219809.
   PubMed Web of Science ®Google Scholar
• A. Molinari, A. Oliva, M. Arismendi-Macuer, L. Guzmán, W. Acevedo, D. Aguayo, R. Vinet, and A. San Feliciano, “Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors,” Molecules 24, no. 12 (2019): 2261. doi:10.3390/molecules24122261.
   PubMed Web of Science ®Google Scholar
• S. Sisodiya, P. Subarno, H. Chaudhary, P. Grewal, G. Kumar, D. P. Daniel, B. Das, D. Nayak, S. K. Guchhait, C. N. Kundu, et al, “Exploration of Benzo[b]Carbazole-6,11-Diones as Anticancer Agents: Synthesis and Studies of hTopoIIα Inhibition and Apoptotic Effects,” Bioorganic & Medicinal Chemistry Letters 49, no. 49 (2021): 128274. (2021) doi:10.1016/j.bmcl.2021.128274.
   PubMedGoogle Scholar
• A. Molinari, A. Oliva, C. Ojeda, J. M. Miguel Del Corral, M. A. Castro, M. Faustino, and A. San Feliciano, “Synthesis and Evaluation as Antitumor Agents of 1,4-Naphthohydroquinone Derivatives Conjugated with Amino Acids and Purines,” Archiv Der Pharmazie 346, no. 12 (2013): 882–90. (2013) doi:10.1002/ardp.201300137.
   PubMed Web of Science ®Google Scholar
• T. Sander, J. Freyss, M. Von Kor, and C. Rufener, “DataWarrior: An Open-Source Program for Chemistry Aware Data Visualization and Analysis,” Journal of Chemical Information and Modeling 55, no. 2 (2015): 460–73. doi:10.1021/ci500588j.
   PubMed Web of Science ®Google Scholar
• C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings,” Advanced Drug Delivery Reviews 64 (2012): 4–17. doi:10.1016/j.addr.2012.09.019.
   Web of Science ®Google Scholar
• W. L. Jorgensen, and E. M. Duffy, “Prediction of Drug Solubility from Structure,” Advanced Drug Delivery Reviews 54, no. 3 (2002): 355–66. doi:10.1016/S0169-409X(02)00008-X.
   PubMed Web of Science ®Google Scholar
• H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne, “The Protein Data Bank,” Nucleic Acids Research 28, no. 1 (2000): 235–42. doi:10.1107/S0907444902003451.
   PubMed Web of Science ®Google Scholar
• D. A. J. Ahmad, O. H. Negm, M. L. Alabdullah, S. Mirza, M. R. Hamed, V. Band, A. R. Green, I. O. Ellis, and E. A. Rakha, “Clinicopathological and Prognostic Significance of Mitogen-Activated Protein Kinases (MAPK) in Breast Cancers,” Breast Cancer Research and Treatment 159, no. 3 (2016): 457–67. doi:10.1007/s10549-016-3967-9.
   PubMed Web of Science ®Google Scholar
• A. R. Sepulveda, “Helicobacter, Inflammation, and Gastric Cancer,” Current Pathobiology Reports 1, no. 1 (2013): 9–18. doi:10.1007/s40139-013-0009-8.
   PubMedGoogle Scholar
• O. Abdel-Rahman, “Targeting Vascular Endothelial Growth Factor (VEGF) Pathway in Gastric Cancer: Preclinical and Clinical Aspects,” Critical Reviews in Oncology/Hematology 93, no. 1 (2015): 18–27. doi:10.1016/j.critrevonc.2014.05.012.
   PubMed Web of Science ®Google Scholar
• P. Khanna, P. J. Chua, B. H. Bay, and G. H. Baeg, “The JAK/STAT Signaling Cascade in Gastric Carcinoma (Review),” International Journal of Oncology 47, no. 5 (2015): 1617–26. doi:10.3892/ijo.2015.3160.
   PubMed Web of Science ®Google Scholar
• C. Y. Xu, J. L. Guo, Z. N. Jiang, S. D. Xie, J. G. Shen, J. Y. Shen, and L. B. Wang, “Prognostic Role of Estrogen Receptor Alpha and Estrogen Receptor Beta in Gastric Cancer,” Annals of Surgical Oncology 17, no. 9 (2010): 2503–9. doi:10.1245/s10434-010-1031-2.
   PubMed Web of Science ®Google Scholar
• S. C. Hewitt, J. F. Couse, and K. S. Korach, “Estrogen Receptor Transcription and Transactivation: Estrogen Receptor Knockout Mice: what Their Phenotypes Reveal about Mechanisms of Estrogen Action,” Breast Cancer Research: BCR 2, no. 5 (2000): 345–52. doi:10.1186/bcr79.
   PubMed Web of Science ®Google Scholar
• O. Trott, and A. J. Olson, “AutoDock Vina: improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading,” Journal of Computational Chemistry 31, no. 2 (2010): 455–61. doi:10.1002/jcc.21334.
   PubMed Web of Science ®Google Scholar
• W. Humphrey, A. Dalke, and K. Schulten, “VMD: Visual Molecular Dynamics,” Journal of Molecular Graphics 14, no. 1 (1996): 33–8. doi:10.1016/0263-7855(96)00018-5.
   PubMedGoogle Scholar
• A. C. Wallace, R. A. Laskowski, and J. M. Thornton, “LIGPLOT: A Program to Generate Schematic Diagrams of Protein-Ligand Interactions,” Protein Engineering 8, no. 2 (1995): 127–34. doi:10.1093/protein/8.2.127.
   PubMedGoogle Scholar
• A. Molinari, A.Oliva, M. Arismendi, E. Imbarack, C. Gálvez, J. Maldonado, and A. S. Feliciano, “The Synthesis of Some Fused Pyrazolo-1,4-Naphthoquinones,” Journal of Heterocyclic Chemistry 52, no. 2 (2015): 620–2. doi:10.1002/jhet.2082.
   Web of Science ®Google Scholar
• P. L. Gaikwad, P. S. Gandhi, D. M. Jagdale, and V. J. Kadam, “The Use of Bioisosterism in Drug Design and Molecular Modification” American Journal of PharmTech Research 2, no. 24 (2012):1–23
   Google Scholar
• X. Zhang, B. Li, M. Song, and J. Song, “Expression and Significance of ERK Protein in Human Breast Carcinoma,” Chinese Journal of Cancer Research 16, no. 4 (2004): 269–73. doi:10.1007/s11670-004-0041-7.
   Google Scholar
• B. Singh, J. Berry, A. Shoher, V. Ramakrishnan, and A. Lucci, “Cox-2 overexpression increases motility and invasion of breast cancer cells,” Annals of Surgical Oncology 26, no. 5 (2005):1393-9. doi:10.1007/BF02523970.
   Web of Science ®Google Scholar
• J. Ma, L. Qin, and X. Li, “Role of STAT3 Signaling Pathway in Breast Cancer,” Cell Communication and Signaling: CCS 18, no. 1 (2020): 33. doi:10.1186/s12964-020-0527-z.
   PubMed Web of Science ®Google Scholar
• M. Hale, J. Janetka, F. Maltais, J. Cao, and R. Mashal, “Izoxazoles and Its Use as Inhibitors of the ERK,” (Patent ES2269458T3, filed September 5, 2001, and issued June 11, 2003).
   Google Scholar
• C. Peifer, M. Abadleh, J. Bischof, D. Hauser, V. Schattel, H. Hirner, U. Knippschild, and S. Laufer, “3,4-Diaryl-Isoxazoles and -Imidazoles as Potent Dual Inhibitors of p38alpha Mitogen Activated Protein Kinase and Casein Kinase 1delta,” Journal of Medicinal Chemistry 52, no. 23 (2009): 7618–30. doi:10.1021/jm9005127.
   PubMed Web of Science ®Google Scholar
• S. A. Laufer, S. Margutti, and M. D. Fritz, “Substituted Isoxazoles as Potent Inhibitors of p38 MAP Kinase,” Chemmedchem. 1, no. 2 (2006): 197–207. doi:10.1002/cmdc.200500025.
   PubMed Web of Science ®Google Scholar
• A. Zarghi, and S. Arfaei, “Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships,” Iranian Journal of Pharmaceutical Research: IJPR 10, no. 4 (2011): 655–83.
   PubMed Web of Science ®Google Scholar
• M. Peng, J. Deng, S. Zhou, D. Xiao, J. Long, N. Zhang, C. He, M. Mo, and X. Yang, “Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth,” Frontiers in Pharmacology 10 (2019): 1159. doi:10.3389/fphar.2019.01159.
   PubMed Web of Science ®Google Scholar
• Y. F. Chen, C. H. Chang, Z. N. Huang, Y. C. Su, S. J. Chang, and J. S. Jan, “The JAK Inhibitor Antcin H Exhibits Direct Anticancer Activity While Enhancing Chemotherapy against LMP1-Expressed Lymphoma,” Leukemia & Lymphoma 60, no. 5 (2019): 1193–203. doi:10.1080/10428194.2018.1512709.
   PubMed Web of Science ®Google Scholar
• E. Martinelli, T. Troiani, E. D'Aiuto, F. Morgillo, D. Vitagliano, A. Capasso, S. Costantino, L. P. Ciuffreda, F. Merolla, L. Vecchione, et al, “Antitumor Activity of Pimasertib, a Selective MEK 1/2 Inhibitor, in Combination with PI3K/mTOR Inhibitors or with Multi-Targeted Kinase Inhibitors in Pimasertib-Resistant Human Lung and Colorectal Cancer Cells,” International Journal of Cancer 133, no. 9 (2013): 2089–101. doi:10.1002/ijc.28236.
   PubMed Web of Science ®Google Scholar
• Á. P. Hernández, P. Chamorro, M. L. Rodríguez, J. M. Miguel Del Corral, P. A. García, A. Francesch, A. San Feliciano, and M. A. Castro, “New Antineoplastic Naphthohydroquinones Attached to Labdane and Rearranged Diterpene Skeletons,” Molecules 26, no. 2 (2021): 474. doi:10.3390/molecules26020474.
   PubMed Web of Science ®Google Scholar